-
In 2021, the trend of drug enterprise differentiation will become more and more obvious
Time of Update: 2021-03-07
the trend of growth, of course, there are enterprises sales fell sharply. from the three-quarter reports issued by various pharmaceutical companies, special one pharmaceutical industry, guangzheng ophthalmology, Ha Sanlian, Zixin pharmaceutical
-
The most noteworthy antibody drug of 2021
Time of Update: 2021-03-06
and children, including newborns born to mothers who test positive for the Ebola virus RT-PCR in Zaire, to treat infections caused by the Zaire Ebolavirus virus. Ebanga is the second Ebola treatment approved by the FDA after the regenerative
-
Time is ahead again! An Italian woman has been infected with the new coronavirus in November 2019
Time of Update: 2021-03-06
An international research team led by the University of Milan in Italy found the genetic sequence of the new coronavirus from a biopsy sample taken by a young female dermatology patient in the country on November 10, 2019, an Italian media outlet
-
The first CAR-T in China is coming! Fosun Kate Aquilonsai injections are about to be approved
Time of Update: 2021-03-06
From NMPA's official website, Aquilonsai Injection, codentag FKC876, Fosun Kate introduced YESCARTA (Axicabtagene Ciloleucel) technology from Kite Pharma in the United States and is authorized to localize the production of targeted CD19 self-contained CAR-T cell therapy products in China.
-
Authoritative Report: 2020 Global Health Investment and Financing Record China's performance?
Time of Update: 2021-03-06
investment in all of the healthcare sub-sectors has broken records, with the venture capital-backed biopharma and diagnostic/tools industries performing well against the new crown pandemic.
-
Another exploration of the reform of the annual salary system of public hospitals!
Time of Update: 2021-03-06
, the director of public hospitals, the annual salary system of health care to the country earlier to explore the reform of the annual salary system of deans, when the medical reform star province and city - Fujian Sanming.
-
4 keywords and 7 key issues, interpretation of health care "14th Five-Year Plan" period tasks
Time of Update: 2021-03-06
$20,000 (see table 1). with the gradual improvement of China's pre-rich old situation and the growing demand for healthy and long-lived consumption, China's total health expenditure and GDP ratio will also increase. In formulating the 14th
-
The evolution of health care negotiations and the rise of local innovative drugs | year
Time of Update: 2021-03-06
As 2020 passed, this year's memorabilia of the pharmaceutical industry was dominated by a sudden new crown outbreak, drawing a line under the national health-care negotiations that have boiled over the industry. the former created a lot
-
2020 inventory: What has changed in the layout of "biomedicine" of Gao's capital, and what is the investment logic?
Time of Update: 2021-03-06
for clinical trials of the drug to be developed for the treatment of HR-in-class metastases. (4) Hualan Vaccines (A20641) In March 2020, Hualan Biological Vaccines Co., Ltd. (hereinafter referred to as Hualan Vaccines) jointly invested
-
To enhance Aubudini's access, Novarcen Jianhua has reached a strategic partnership for commercial insurance innovation
Time of Update: 2021-03-06
On January 11, No cheng Jianhua announced that the company recently signed a cooperation framework agreement with Shanghai Magnesium Health Technology Co., Ltd. (called Magnesium Health), the two sides will be through the integration of medical
-
Koren, Yangzijiang... 57 new drugs reported clinically! Zhengda Qing the first inhaler class 1 new drug debut, Qilu's first oral dissolved membrane came
Time of Update: 2021-03-06
(2020.12.26-2021.1.8) New drug listing application review status update domestic class 1 new drug Sovantini capsule was approved for market, the product is and Huang Pharmaceutical independently developed a new oral tyrosine kinase inhibitor, with anti-angiogenesic and immunomodulation dual activity.
-
Health Insurance Bureau No. 1 Wenli pushed the online medical insurance settlement and offline delivery of medicine door-to-door! Full landing during the year
Time of Update: 2021-03-06
people to seek medical treatment difficulties. First eat crab to win the first opportunity in fact, Shandong Province dares in 2021 No. 1 document proposed in the end of 2021 within the deadline, to achieve mobility-reducing elderly re-diagnosis
-
CDE proposed breakthrough therapy identified: Amjin KRAS inhibitor AMG 510 treatment NSCLC
Time of Update: 2021-03-06
occurs in about 25% of cancer cases, mainly in lung, pancreatic and colorectal cancers, and is associated with very poor disease prognostois. , KRASG12C mutation is one of the most common KRAS mutations, specifically kras 12-bit glycine mutation
-
2020 Domestic CRO Industry Review
Time of Update: 2021-03-06
key materials to fight the outbreak include testing reagents, vaccines, drugs, and some medical devices, and research and development and production units are working overtime, with CRO companies that can provide supporting services.
-
Medici partner Shengnoki "first-in-class" new drug up to III
Time of Update: 2021-03-06
receptor (estrogen receptor, ER) has inhibition activity, since then, for masturbation amniotic acid in the pharmaceutical aspects of research has been carried out. Current studies of Acolatin's anti-tumor mechanisms have shown that it regulates
-
ORR up to 79%! The results of the advanced NSCLC for the first-line treatment of Beda Pharmaceuticals Ectinib were announced
Time of Update: 2021-03-06
non-small cell lung cancer with EGFR mutations. Screenshot Source: Reference: Ektinib is a powerful, highly selective oral EGFR-TKI developed by Beda Pharmaceuticals over a period of nearly a decade and belongs to class 1 innovative drugs. <br
-
Clinical transition smooth patients benefit most obviously - the collection of crown vein stent "landing" the first week of observation
Time of Update: 2021-03-06
and cities, including Beijing, Tianjin, Hunan, Shanxi and Xinjiang (including the Corps). reporter learned that, although the price of stents dropped significantly, but many medical institutions carried out by the persethopal coronary artery
-
3 new drugs to be included in the priority review!
Time of Update: 2021-03-06
Supi Medicine's new rare disease drug Nitesinon capsules, the proposed development of adaptive disorders are: combined with tyrosine and phenylalanine dietary restrictions, for the treatment of adult and pediatric patients (at any age) hereditary HT-1.
-
Junshi Ripley single resistance was approved for Phase III clinical overlay by fda fast track eligibility overlay
Time of Update: 2021-03-05
treatment in patients with mucosal melanoma was also approved by the FDA. The first approved domestic PD-1 single anti-2018 December 2018, Junshi biotrepri single anti-injection in china obtained the conditional approval of NMPA listing
-
How should we deal with the reform of the payment method of health insurance when it meets the medical association?
Time of Update: 2021-03-05
As one of the five basic medical and health systems in China, the establishment and perfection of the hierarchical diagnosis and treatment system has attracted much attention. Medical union" (referred to as "medical union") is a feasible way
